tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CYTK Stock Latest News

Cytokinetics price target raised to $87 from $82 at RBC Capital
The FlyCytokinetics price target raised to $87 from $82 at RBC Capital
13h ago
CYTK
Cytokinetics price target raised to $90 from $80 at B. Riley
PremiumThe Fly
Cytokinetics price target raised to $90 from $80 at B. Riley
2d ago
BMY
CYTK
Cytokinetics presents additional data from MAPLE-HCM
PremiumThe Fly
Cytokinetics presents additional data from MAPLE-HCM
2d ago
CYTK
Promising Potential of Cytokinetics’ Aficamten Drives Buy Rating Amid Anticipated U.S. Approval
PremiumRatings
Promising Potential of Cytokinetics’ Aficamten Drives Buy Rating Amid Anticipated U.S. Approval
2d ago
CYTK
Private Markets: Anthropic projects $70B in revenue in 2028
PremiumThe Fly
Private Markets: Anthropic projects $70B in revenue in 2028
4d ago
S
BMY
Cytokinetics (CYTK) Faces Class Action Over Misleading Aficamten Claims  
PremiumMarket NewsCytokinetics (CYTK) Faces Class Action Over Misleading Aficamten Claims  
5d ago
CYTK
Cytokinetics’ Earnings Call: Progress and Challenges
Premium
Company Announcements
Cytokinetics’ Earnings Call: Progress and Challenges
5d ago
CYTK
Strategic Positioning and Launch Readiness Propel Cytokinetics to ‘Buy’ Rating
Premium
Ratings
Strategic Positioning and Launch Readiness Propel Cytokinetics to ‘Buy’ Rating
6d ago
CYTK
Cytokinetics price target raised to $63 from $62 at BofA
PremiumThe Fly
Cytokinetics price target raised to $63 from $62 at BofA
6d ago
CYTK
Cytokinetics’ Market Uncertainty and Competitive Pressures Lead to Hold Rating
PremiumRatings
Cytokinetics’ Market Uncertainty and Competitive Pressures Lead to Hold Rating
6d ago
CYTK
Cytokinetics’ Q3 2025: Progress in Cardiac Therapies
PremiumCompany Announcements
Cytokinetics’ Q3 2025: Progress in Cardiac Therapies
6d ago
CYTK
Cytokinetics reports Q3 EPS ($2.55), consensus ($1.57)
PremiumThe Fly
Cytokinetics reports Q3 EPS ($2.55), consensus ($1.57)
6d ago
CYTK
Cytokinetics price target raised to $70 from $55 at JPMorgan
PremiumThe FlyCytokinetics price target raised to $70 from $55 at JPMorgan
9d ago
CYTK
CYTK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
CYTK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
9d ago
CYTK
Major Moves: Fifth Third, HEICO, Transdigm, Cytokinetics, Vor Biopharma
Premium
Weekend Updates
Major Moves: Fifth Third, HEICO, Transdigm, Cytokinetics, Vor Biopharma
18d ago
HEI
TDG
Cytokinetics price target raised to $62 from $56 at BofA
PremiumThe Fly
Cytokinetics price target raised to $62 from $56 at BofA
22d ago
CYTK
Cytokinetics’ Aficamten Faces Competitive and Regulatory Challenges: Hold Rating Maintained
PremiumRatings
Cytokinetics’ Aficamten Faces Competitive and Regulatory Challenges: Hold Rating Maintained
22d ago
CYTK
Verisign, HEICO, Transdigm, Albertsons, Cytokinetics: Insider Moves Unveiled!
PremiumWeekend Updates
Verisign, HEICO, Transdigm, Albertsons, Cytokinetics: Insider Moves Unveiled!
25d ago
ACI
HEI
Cytokinetics price target raised to $82 from $71 at Barclays
PremiumThe Fly
Cytokinetics price target raised to $82 from $71 at Barclays
1M ago
CYTK
Cytokinetics price target raised to $56 from $52 at BofA
PremiumThe FlyCytokinetics price target raised to $56 from $52 at BofA
1M ago
CYTK
Promising Trial Results and Safety Profile of Aficamten Boost Cytokinetics’ Stock Outlook
Premium
Ratings
Promising Trial Results and Safety Profile of Aficamten Boost Cytokinetics’ Stock Outlook
1M ago
CYTK
Promising Data from HFSA and Long-term Efficacy of Aficamten Lead to Buy Rating for Cytokinetics
Premium
Ratings
Promising Data from HFSA and Long-term Efficacy of Aficamten Lead to Buy Rating for Cytokinetics
1M ago
CYTK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >